002332SZSE

Announcement on Obtaining Domestic Production Drug Registration Certificate for Betahistine Mesilate Tablets

✨ AI Summary

Zhejiang Xianju Pharmaceutical Co., Ltd. announced it has obtained a drug registration certificate from the NMPA for its domestically produced Betahistine Mesilate Tablets. This approval enriches the company's product line and enhances market competitiveness. The drug is indicated for vertigo and dizziness associated with Meniere's disease and similar conditions. The company's product is classified as a chemical drug, Category 4.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 002332 Securities Abbreviation: Xianju Pharmaceutical Announcement No.: 2026-024

Zhejiang Xianju Pharmaceutical Co., Ltd. Announcement on Obtaining Domestic Production Drug Registration Certificate for Betahistine Mesilate Tablets

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or material omissions.

Zhejiang Xianju Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received the "Drug Registration Certificate" (Certificate No.: 2026S01523) issued by the National Medical Products Administration for Betahistine Mesilate Tablets, and the Company's Betahistine Mesilate Tablets have been approved for registration. The relevant situation is announced as follows:

I. Basic Information of the Drug

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.